The Experts below are selected from a list of 768 Experts worldwide ranked by ideXlab platform
Massimo Franchini - One of the best experts on this subject based on the ideXlab platform.
-
beyond immunohaematology the role of the abo blood group in human diseases
Vox Sanguinis, 2013Co-Authors: Giancarlo M Liumbruno, Massimo FranchiniAbstract:The antigens of the ABO blood group system (A, B and H determinants, respectively) are complex carbohydrate molecules on the extracellular surface of red blood cell membranes1. However, along with their expression on red blood cells, ABO antigens are also highly expressed on the surface of a variety of human cells and tissues, including the epithelium, sensory neurons, platelets, and the vascular endothelium2. Thus, the clinical significance of the ABO blood group system extends beyond transfusion medicine and several reports have suggested an important involvement in the development of cardiovascular, oncological and other diseases3,4. Current knowledge on the association between the ABO blood group system and various human diseases are summarised in this narrative review.
-
the demand for factor viii and for factor ix and the toll fractionation product surplus management
Blood Transfusion, 2013Co-Authors: Gabriele Calizzani, Massimo Franchini, Giancarlo M Liumbruno, Samantha Profili, Fabio Candura, Monica Lanzoni, Stefania Vaglio, Livia Cannata, Pier Mannuccio Mannucci, Giuliano GrazziniAbstract:1Italian National Blood Centre, National Institute of Health, Rome; 2Scientific Direction, IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, Milan; 3Faculty of Medicine and Psychology "Sapienza" University of Rome; 4Immunohematology, Medicine and Clinical Pathology Units, "San Giovanni Calibita" Fatebenefratelli Hospital, AFAR, Rome; 5Department of Transfusion Medicine and Haematology, Carlo Poma Hospital, Mantua, Italy
-
abo blood group old dogma new perspectives
Clinical Chemistry and Laboratory Medicine, 2013Co-Authors: Massimo Franchini, Giancarlo M LiumbrunoAbstract:Human blood group antigens are glycoproteins and glycolipids expressed on the surface of red blood cells and a variety of human tissues, including the epithelium, sensory neurons, platelets and the vascular endothelium. Accumulating evidence indicate that ABO blood type is implicated in the development of a number of human diseases, including cardiovascular and neoplastic disorders. In this review, beside its physiologic role in Immunohematology and transfusion medicine, we summarize the current knowledge on the association between the ABO blood group and the risk of developing thrombotic events and cancers.
Giancarlo M Liumbruno - One of the best experts on this subject based on the ideXlab platform.
-
beyond immunohaematology the role of the abo blood group in human diseases
Vox Sanguinis, 2013Co-Authors: Giancarlo M Liumbruno, Massimo FranchiniAbstract:The antigens of the ABO blood group system (A, B and H determinants, respectively) are complex carbohydrate molecules on the extracellular surface of red blood cell membranes1. However, along with their expression on red blood cells, ABO antigens are also highly expressed on the surface of a variety of human cells and tissues, including the epithelium, sensory neurons, platelets, and the vascular endothelium2. Thus, the clinical significance of the ABO blood group system extends beyond transfusion medicine and several reports have suggested an important involvement in the development of cardiovascular, oncological and other diseases3,4. Current knowledge on the association between the ABO blood group system and various human diseases are summarised in this narrative review.
-
the demand for factor viii and for factor ix and the toll fractionation product surplus management
Blood Transfusion, 2013Co-Authors: Gabriele Calizzani, Massimo Franchini, Giancarlo M Liumbruno, Samantha Profili, Fabio Candura, Monica Lanzoni, Stefania Vaglio, Livia Cannata, Pier Mannuccio Mannucci, Giuliano GrazziniAbstract:1Italian National Blood Centre, National Institute of Health, Rome; 2Scientific Direction, IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, Milan; 3Faculty of Medicine and Psychology "Sapienza" University of Rome; 4Immunohematology, Medicine and Clinical Pathology Units, "San Giovanni Calibita" Fatebenefratelli Hospital, AFAR, Rome; 5Department of Transfusion Medicine and Haematology, Carlo Poma Hospital, Mantua, Italy
-
abo blood group old dogma new perspectives
Clinical Chemistry and Laboratory Medicine, 2013Co-Authors: Massimo Franchini, Giancarlo M LiumbrunoAbstract:Human blood group antigens are glycoproteins and glycolipids expressed on the surface of red blood cells and a variety of human tissues, including the epithelium, sensory neurons, platelets and the vascular endothelium. Accumulating evidence indicate that ABO blood type is implicated in the development of a number of human diseases, including cardiovascular and neoplastic disorders. In this review, beside its physiologic role in Immunohematology and transfusion medicine, we summarize the current knowledge on the association between the ABO blood group and the risk of developing thrombotic events and cancers.
Willy A Flegel - One of the best experts on this subject based on the ideXlab platform.
-
molecular immunohaematology round table discussions at the aabb annual meeting philadelphia 2014
Vox Sanguinis, 2016Co-Authors: Willy A Flegel, Joann M Moulds, Margaret A Keller, Ellen Klapper, Gary Stack, Maryse Stlouis, Christopher A Tormey, F Noizatpirenne, Nadine Shehata, D A WaxmanAbstract:Use of molecular-based immunohaematology testing is becoming more widespread worldwide in laboratories that are accustomed to the use of blood group serology alone. Molecular immunohaematology issues may be challenging even for some established professionals in the field of blood group serology. At an international meeting, we offered round table discussions on four patient-related and two donor-related topics, which are current and possibly controversial. Six molecular immunohaematology questions were addressed: applications for highly contagious infections, such as Ebola; utility after transfusions in the preceding three months; root cause analysis for unexplained occurrence of anti-D; acceptable turnaround time for red cell genotyping of patients; criteria for donor cohorts to be genotyped; and quality assurance for discrepancies between serological phenotype and licensed red cell genotyping. The opinions polled in this workshop with an international assemblage of more than 100 transfusion medicine specialists were discussed in the light of education and training opportunities and the development of guidance in the field. We provide a summary report of the participants’ input to our questions and discuss the topics.
-
molecular immunohaematology round table discussions at the aabb annual meeting denver 2013
Blood Transfusion, 2015Co-Authors: Willy A Flegel, Joann M Moulds, Susan T Johnson, Margaret A Keller, Ellen Klapper, Hanh Khuu, Axel Seltsam, Gary Stack, Maryse Stlouis, Christopher A TormeyAbstract:Well trained, experienced serologists in transfusion medicine laboratories have been familiar with blood group serology for decades. With the advent of molecular immunohaematology, there is a need to adopt and embrace the clinical and diagnostic applications in order for patients to benefit from the advances that this technology offers1–3. We organised an international forum to discuss molecular immunohaematology concepts that may be challenging even for some established professionals in the field of serology. The objectives of the session were two-fold. First, the session allowed networking among immunohaematology professionals who have an interest in the application of molecular immuno-haematology and blood group genetics while meeting with leaders in the field of molecular immunohaematology. By giving input and asking questions, the participants could define their knowledge relative to the experience of the group as a whole. Second, the discussions and the input from experienced professionals were recorded. This approach allowed documentation of current knowledge, as well as acceptance and concerns of the participants. It is useful to gathering information in this field, because the perception at the level of the participants is critical for shaping the adoption of molecular immunohaematology. We provide a summary report of the items discussed and issues raised by the participants. The results describe the status of molecular immunohaematology within this large group of experienced professionals in transfusion medicine laboratories and can guide targeted educational efforts.
-
applying molecular immunohaematology to regularly transfused thalassaemic patients in thailand
Vox Sanguinis, 2014Co-Authors: Pairaya Rujirojindakul, Willy A FlegelAbstract:Background Red blood cell transfusion is the principal therapy in patients with severe thalassaemias and haemoglobinopathies, which are prevalent in Thailand. Serological red blood cell typing is confounded by chronic transfusion, because of circulating donor red blood cells. We evaluated the concordance of serological phenotypes between a routine and a reference laboratory and with red cell genotyping. Materials and methods Ten consecutive Thai patients with β-thalassemia major who received regular transfusions were enrolled in Thailand. Phenotypes were tested serologically at Songklanagarind Hospital and at the National Institutes of Health. Red blood cell genotyping was performed with commercially available kits and a platform. Results In only three patients was the red cell genotyping concordant with the serological phenotypes for five antithetical antigen pairs in four blood group systems at the two institutions. At the National Institutes of Health, 32 of the 100 serological tests yielded invalid or discrepant results. The positive predictive value of serology did not reach 1 for any blood group system at either of the two institutions in this set of ten patients. Discussion Within this small study, numerous discrepancies were observed between serological phenotypes at the two institutes; red cell genotyping enabled determination of the blood group when serology failed due to transfused red blood cells. We question the utility of serological tests in regularly transfused paediatric patients and propose relying solely on red cell genotyping, which requires training for laboratory personnel and physicians. Red cell genotyping outperformed red cell serology by an order of magnitude in regularly transfused patients.
Christopher A Tormey - One of the best experts on this subject based on the ideXlab platform.
-
molecular immunohaematology round table discussions at the aabb annual meeting philadelphia 2014
Vox Sanguinis, 2016Co-Authors: Willy A Flegel, Joann M Moulds, Margaret A Keller, Ellen Klapper, Gary Stack, Maryse Stlouis, Christopher A Tormey, F Noizatpirenne, Nadine Shehata, D A WaxmanAbstract:Use of molecular-based immunohaematology testing is becoming more widespread worldwide in laboratories that are accustomed to the use of blood group serology alone. Molecular immunohaematology issues may be challenging even for some established professionals in the field of blood group serology. At an international meeting, we offered round table discussions on four patient-related and two donor-related topics, which are current and possibly controversial. Six molecular immunohaematology questions were addressed: applications for highly contagious infections, such as Ebola; utility after transfusions in the preceding three months; root cause analysis for unexplained occurrence of anti-D; acceptable turnaround time for red cell genotyping of patients; criteria for donor cohorts to be genotyped; and quality assurance for discrepancies between serological phenotype and licensed red cell genotyping. The opinions polled in this workshop with an international assemblage of more than 100 transfusion medicine specialists were discussed in the light of education and training opportunities and the development of guidance in the field. We provide a summary report of the participants’ input to our questions and discuss the topics.
-
molecular immunohaematology round table discussions at the aabb annual meeting denver 2013
Blood Transfusion, 2015Co-Authors: Willy A Flegel, Joann M Moulds, Susan T Johnson, Margaret A Keller, Ellen Klapper, Hanh Khuu, Axel Seltsam, Gary Stack, Maryse Stlouis, Christopher A TormeyAbstract:Well trained, experienced serologists in transfusion medicine laboratories have been familiar with blood group serology for decades. With the advent of molecular immunohaematology, there is a need to adopt and embrace the clinical and diagnostic applications in order for patients to benefit from the advances that this technology offers1–3. We organised an international forum to discuss molecular immunohaematology concepts that may be challenging even for some established professionals in the field of serology. The objectives of the session were two-fold. First, the session allowed networking among immunohaematology professionals who have an interest in the application of molecular immuno-haematology and blood group genetics while meeting with leaders in the field of molecular immunohaematology. By giving input and asking questions, the participants could define their knowledge relative to the experience of the group as a whole. Second, the discussions and the input from experienced professionals were recorded. This approach allowed documentation of current knowledge, as well as acceptance and concerns of the participants. It is useful to gathering information in this field, because the perception at the level of the participants is critical for shaping the adoption of molecular immunohaematology. We provide a summary report of the items discussed and issues raised by the participants. The results describe the status of molecular immunohaematology within this large group of experienced professionals in transfusion medicine laboratories and can guide targeted educational efforts.
D A Waxman - One of the best experts on this subject based on the ideXlab platform.
-
molecular immunohaematology round table discussions at the aabb annual meeting philadelphia 2014
Vox Sanguinis, 2016Co-Authors: Willy A Flegel, Joann M Moulds, Margaret A Keller, Ellen Klapper, Gary Stack, Maryse Stlouis, Christopher A Tormey, F Noizatpirenne, Nadine Shehata, D A WaxmanAbstract:Use of molecular-based immunohaematology testing is becoming more widespread worldwide in laboratories that are accustomed to the use of blood group serology alone. Molecular immunohaematology issues may be challenging even for some established professionals in the field of blood group serology. At an international meeting, we offered round table discussions on four patient-related and two donor-related topics, which are current and possibly controversial. Six molecular immunohaematology questions were addressed: applications for highly contagious infections, such as Ebola; utility after transfusions in the preceding three months; root cause analysis for unexplained occurrence of anti-D; acceptable turnaround time for red cell genotyping of patients; criteria for donor cohorts to be genotyped; and quality assurance for discrepancies between serological phenotype and licensed red cell genotyping. The opinions polled in this workshop with an international assemblage of more than 100 transfusion medicine specialists were discussed in the light of education and training opportunities and the development of guidance in the field. We provide a summary report of the participants’ input to our questions and discuss the topics.
